Recursion Pharmaceuticals (NASDAQ:RXRX) Sees Large Volume Increase - Still a Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) saw unusually-high trading volume on Thursday . Approximately 19,902,525 shares changed hands during trading, an increase of 15% from the previous session's volume of 17,352,523 shares.The stock last traded at $7.93 and had previously closed at $7.92.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on RXRX. KeyCorp dropped their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 8th. Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday.

Recursion Pharmaceuticals Trading Up 3.5 %

The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The business's fifty day moving average price is $7.15 and its two-hundred day moving average price is $6.90.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $26.08 million for the quarter, compared to the consensus estimate of $12.62 million. During the same quarter last year, the business earned ($0.43) earnings per share. Recursion Pharmaceuticals's quarterly revenue was up 147.6% on a year-over-year basis. On average, research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insider Activity

In related news, CFO Michael Secora sold 15,000 shares of the firm's stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the transaction, the chief financial officer now directly owns 1,499,631 shares in the company, valued at approximately $11,487,173.46. This trade represents a 0.99 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Blake Borgeson sold 11,447 shares of the business's stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total transaction of $87,455.08. Following the transaction, the director now directly owns 7,066,113 shares of the company's stock, valued at approximately $53,985,103.32. This represents a 0.16 % decrease in their position. The disclosure for this sale can be found here. 15.75% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of RXRX. The Manufacturers Life Insurance Company boosted its holdings in Recursion Pharmaceuticals by 32.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 111,613 shares of the company's stock valued at $837,000 after purchasing an additional 27,440 shares during the period. Algert Global LLC acquired a new position in Recursion Pharmaceuticals in the second quarter worth about $129,000. SG Americas Securities LLC lifted its position in shares of Recursion Pharmaceuticals by 249.0% during the 3rd quarter. SG Americas Securities LLC now owns 89,325 shares of the company's stock worth $589,000 after buying an additional 63,727 shares during the period. Handelsbanken Fonder AB boosted its stake in shares of Recursion Pharmaceuticals by 33.4% in the 3rd quarter. Handelsbanken Fonder AB now owns 69,500 shares of the company's stock valued at $458,000 after purchasing an additional 17,400 shares in the last quarter. Finally, San Luis Wealth Advisors LLC acquired a new position in Recursion Pharmaceuticals in the third quarter valued at about $69,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.